“You mean you’ve never heard of spectroscopy being used in
prostate cancer staging?” Don, a recently diagnosed prostate cancer
(PC) patient, was astonished to learn that the doctor treating him was
unaware of this application of this new technology. Don had been
doing his own research on the Internet about MRI scanning of the
prostate. And he came across information about this new enhancement
to MRI that improves the doctor's ability to localize the cancer
within the prostate gland.
Newly diagnosed PC patients who face this
situation are understandably surprised and upset
when faced with the realization that there is
medical information relevant to their treatment
that their doctor is totally unfamiliar with. Actually
this is not so surprising when we consider
the explosive growth rate of new medical information.
After all, how can one doctor, whether a
General Practitioner or a specialist such as a
urologist, a medical
oncologist, or a radiation
oncologist, be an all-knowing expert for such a
large number of diseases and treatments? Consider the plight of urologists, for example.
Even though they specialize “narrowly” in
diseases of the urinary system, their area of
responsibility demands expertise in a wide variety
of unrelated but important areas such as
infections, kidney stones, congenital defects,
sexual dysfunction, corrective surgery, and a
variety of cancers. The genitourinary system
alone is subject to more than 20 different varieties
of cancer (kidney, bladder, testicular, etc.).
And for each of these 20 varieties, treatment has
to be customized according to the unique grade
and stage each patient manifests.
Staging the Cancer
And yet, you would think that treatment for a
common problem like PC would be straightforward.
After the cancer is staged, it may seem reasonable
to you that your doctor should be able
suggest appropriate treatment options in an
unbiased and understandable way. Unfortunately,
there are a number of complicating factors.
To begin with, even when the best technology
is brought to bear, the true stage of the
cancer can only be estimated and
described in terms of percentages. The
present state of the art for staging uses computerized
algorithms and nomograms (see
Insights, May 2001) for profiling, or to estimate
the likelihood of microscopic spread
(termed metastasis) of the disease outside the
prostate to another area of the body. These computerized
calculations are developed from clinical follow-up studies done on hundreds, sometimes
thousands of men. They are based on
excellent science, but their purpose is to dictate
probabilities, not absolutes, and should be
understood as such.
One of the primary functions of computerized
calculations is to show the likelihood of
microscopic metastases, or micromets. It is
important to know when metastases are present
because if they are, cure with local therapies
such as radiation or surgery is no longer possible. The problem is that metastases, if they are
present, can be microscopic, and therefore
invisible to even our best technology. Their presence
or absence can only be scientifically estimated from the size, grade, and location, of
the primary tumor in the prostate gland.
Accurate information about the primary
tumor then is clearly important, and initial
information is obtained indirectly from blood
tests (PSA),
Transrectal ultrasound (TRUS), and
biopsy results. However, these factors only provide
estimates of the tumor size. So we are
using estimates based on estimates to
guide newly diagnosed men in their
treatment decisions.
Newer scanning techniques attempting to “
see” the size of the cancer within the prostate
gland are growing in use in research protocols
or in university settings, but they are still a long
way from being widely accepted in private practice. High-resolution
ultrasound and spectrographic MRI can both provide additional useful
information, but only if used by radiologists
who are skilled and experienced. As you can see,
the staging process is imperfect and potentially
complicated.
Choosing the Best Treatment
for You
Once the staging process is complete, the next
logical step is soliciting direction from qualified
experts. Studies in the United States have
shown, however, that in the process of rendering
advice about treatment options, urologists usually
recommend surgery, and radiation therapists
usually recommend radiation. I do not
mean to imply that these physicians have less
than the best intentions. It is not at all surprising
that the dedicated individuals who have
spent years of their lives honing therapeutic
skills in a specific medical discipline would
remain convinced that the choice they made
when they decided to undergo such rigorous
training is the best option for their patients. Unfortunately, however, no head-to-head studies
comparing the surgery versus radiation exist
to resolve these controversies.
Quality of Life Considerations
Long-term studies of men with good-risk disease
indicate that the 10-year mortality rates are
now less than 1% regardless of the treatment
selected. The major difference between
treatments today is likely to be quality of
life, not length of life.
So the newly diagnosed PC patient – and
his doctor – are faced with daunting amounts
of existing knowledge, ever-accruing new
knowledge, and imperfect staging knowledge.
In addition, the patient himself, who is usually
frightened and overwhelmed, must consider an
additional big factor – the uniqueness of
his individual situation.
Every man diagnosed with this disease has
specific life goals and personal attitudes toward
sexuality, urinary and
bowel function, and survival
itself. Some treatments, such as hormonal
therapy, can affect physical strength, bone
integrity, stamina, and mood, causing unfamiliar
mood swings and emotions. How can the
medical professionals, even if totally unbiased,
have time to get to know the unique needs and
desires of each individual patient in the space of
a single medical consultation?
Self-Empowerment
Clearly, there is no simple answer to this tangle
of complicated issues. However, the
newly diagnosed cancer patient is far
from helpless. He has two responsibilities. First, he must
become informed himself by doing his own research and by taking responsibility
for knowing as much as he can about
his options. Second, and equally important,
he must be discerning in choosing his primary
resource – his doctor. To these ends, there is
good advice available.
The educational facilitators on the
PCRI Helpline staff use three guiding principles to
counsel men newly diagnosed with PC:
- Do not rush into making a treatment
decision. Wait for the shock of diagnosis to
wear off before embarking on a therapy
that can never be reversed. Take time to
consider what additional tests might be
beneficial to your staging, and what might
give you a better overall understanding of
your particular disease and its aggressiveness.
And make sure that an overall assessment
of the risk for having micro-metastatic
disease has been performed. You can
afford to take the time to perform these
basic steps because PC is usually a slow
growing disease.
- Hear all your options and talk to
experts in all the specialty fields, including
urology, medical oncology, radiation
oncology, and pathology. Try to speak to
known leaders in their respective fields, since
quality medical care improves outcomes.
- Attend patient support
group meetings. These groups typically are run by educated
and empowered patients; they exist for only
one purpose: to help men get unbiased
information and direction about all the different
treatment options. Try to find one
that pursues current research and knows
how to access articles from medical journals.
You will find that most PC survivors
are very generous in sharing their experiences
and their knowledge with you.
What This Means to You
Selecting treatment for PC is a high-stakes
proposition, potentially risking sexual function,
urinary function, even life itself. Can Don ever
go back to dutiful acceptance of a physician's
recommendation without personally critiquing
the proposed treatment plan in light of his own
personal knowledge and understanding? After
reading this article, can you?
Multiple resources exist to help you learn
more about your options before a treatment plan
is selected. Dedication and hard work will be
necessary on your part. At the same time, many
effective organizations and resources exist to
help you along the way. Educating yourself sufficiently
to make an informed decision is possible. Are you ready to embark on this journey to
self-empowerment? PCRI is here to support you,
to work with you, and help you reach that goal.
Editor's note: For information on the staging and treatment of prostate
cancer, we suggest the three part series by Dr. Scholz Newly
Diagnosed PC: Evaluating the Options.
For information on finding resources on the Internet, see the E-Empowerment
article from
PCRI Insights November, 2004 vol. 7, no. 4 by Dr. Arthur Lurvey.
|
Call the PCRI Helpline
Los Angeles: 800-641-7274
or
310-743-2110
Florida: 239-395-0995
Georgia: 770-632-2899
|